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1. INTRODUCTION 
 
The idiopathic inflammatory myopathies (IIM), which collectively are 
also known as myositis, are characterized clinically by muscle weakness, 
decreased muscle endurance and by muscle inflammation. These are rare 
diseases with average incidence of 2,8-7,7/million and prevalence of 5-10/ 
million. The male/female ratio is ½-1/3. Dermatomyositis can occur in children 
and in adults as well. However polymyositis is mainly the disease of adults. 
Considering the ethiology, IIMs are multifactorial disorders, genetic and 
environmental factors (like UV radiation, smoking, infections, medications) also 
influencing the disease onset and course. The pathomechanism is not clearly 
known.  
The leading symptom is progressive weakness of proximal limb 
muscles, causing difficulties with everyday tasks like stair-climbing, combing, 
shaving. All the striated muscles affected, so difficulty in chewing, swallowing, 
breathing difficulty can be present. In IBM not only proximal but also distal 
muscle weakness occurs. General symptoms are fatigue, malaise and weight 
loss. Beside the weakness pain and atrophy can be observed in muscle. Although 
slow onset of muscle fatigue is the most commonly presenting symptom, the 
skin or lungs might also be initially affected. During disease progression, 
symptoms might occur in different organs at different times. Arthralgia and 
arthritis signed the involvment of joints.  Rarely signd of myocardial 
involvement like myocarditis or arrhythmias are present as well. The multi-
organ involvement is generally leads to severe complications and poor 
prognosis. 
The skin symptoms of DM classified into three types, pathognomic 
(diseases specific), characteristic (can occur in other diseases) and less 
frequently occurring symptoms. The skin lesions often accompanied by intense 
itching and photosensitivity is very unpleasant.  
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As in other systhemic autoimmune diseases autoantibodies can also be 
detected in IIM. Main groups are: myositis-associated (MAA) and myositis-
specific (MSA) autoantibodies.  
The dignosis is based on a system of generally accepted criteria by 
Bohan and Peter: 
  
1. criteria: proximal muscle weakness 
2. criteria: positive muscle biopsy 
3. criteria: eleveted enzyme levels in the serum (CK, GOT, GPT, LDH, 
Aldolase)  
4. criteria: myopathic pattern on the electromyogram (EMG) 
5. criteria: characteristic skin rashes in DM 
 
1.2. Subsets based on clinicopathological features 
 
I. Polymyositis (PM) is the most frequent form of IIM, affected mainly 
women between the age 45 and 60. In this subset, proximal and axial muscle 
weakness increase gradully without any pain. 
II. Dermatomyositis (DM) is the most common subset in childhood and 
the second in adults. Considering the gender, women dominancy also presented 
in both group. Juvenile DM is associated with classical skin symptoms, more 
frequent calcification of muscles, severe isomatrophy, rare malignancy and 
association with other connective tissue diseases. In the case of adult DM skin 
symptoms are prevented by the development of muscle weakness and there are 
more tumor association and overlap forms. 
III. Inclusion body myositis: after the age of 50 this is the most common 
chronic progressive muscular disease. It mostly affects men. Symptoms usually, 
start on the lower limbs with proximal and also distal muscle weakness and then 
affect the muscle groups of upper limbs. 
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IV: Necrotyzing autoimmun myopathy: shows similar symptoms as PM 
and DM. This group includes several syndromes different in hystology and 
caracteristics like statin induced NAM, autoantibody induced NAM and cancer 
associated NAM. 
 
1.3. Disease activity, treatment 
 
Based on the recommendation of the International Myositis Assessment & 
Clinical Studies Group (IMACS), 6 so-called "core set measure" tests are used 
to evaluate the disease activity at onset and during the disease course. These 
scores also help us to evaluate the therapic response and effectivity. These 
measures includes muscle strength test, levels of muscle enzymes (CK and 
LDH), extramuscular symptoms, and the changes in overall disease activity 
scored by both patient and physician. 
Before selecting the pharmacological therapy, muscular and extramuscular 
symptoms has to be considered as well as the patient's comorbidities and general 
physical status. High or medium doses of corticosteroids are recommended as 
first line therapy. In case of no improvement of muscle strength after one month 
of steroid therapy, treatment is considered ineffective and additional 
immunosuppressive therapy needs to require. In this case, the so-called second-
line drugs can be used like azathioprine, mycophenolate mofetil, methotrexate, 
cyclosporin A, cyclophosphamide. Also a second-line drug is needed even in 
the first few days when the overall condition of the patient rapidly deteriorates 
and also in case of anti-synthetase syndrome or severe extramuscular 
involvement. If the steroid does not induce remission in severe, rapid 
progressive cases, intravenous immunoglobulin (IVIG) therapy should be 
preferred. In patients who respond to steroids, our aim is to reduce the dose to 
the lowest dose, which will still control the disease. This is also achieved by 
using a "steroid-saving" immunosuppressive therapy. 
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In addition to medication therapy, regular and adequate exercises help 
improve the quality of life. 
 
1.4. Myositis in Hungary 
 
As myositis are rare diseases at the beginning of my PhD work I was trying 
to obtain epidemiological data in Hungary. Searching in the database of National 
Health Insurance Fund Administration and the University of Debrecen I’ve 
identified 1119 new myositis patients diagnosed between 1999 and 2010. The 
average incidence of the disease was found to be 0.95/100.000/year. The 
male/female ratio was 1/1 in children and ½-3 in adults. Dermatomyositis 
occurred both in children and adult, but polymyositis was found mainly in 
adults. These epidemiological data partly correlate with those published in the 
international literature. 
From 1999 to 2010, 289 new patients were hospitalized because of 
myositis in our Clinic. The average age of patients was 47.73 years. The most 
common phenotype in our patients was polymyositis (61.93%) and 
dermatomyositis (32.17%). Other systemic immune diseases, so-called " 
overlap myositis” occurred in 14 cases, 5 cases of Sjögren syndrome, 6 patients 
with progressive systemic sclerosis and 3 patients with rheumatoid arthritis. In 
these 14 overlap syndrome cases, myositis component were PM in 11 and DM 
in 3 patients. 
Tumor-associated myositis was found in 10.72% of our patients. 
Autoantibodies were detected in 57.43% of patients (n = 166). Frequency of 
myositis-associated autoantibodies were 35.64% (n = 103) in the serum of our 
patients. 
 
1.5. Vascular changes in IIM 
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Several autoimmune rheumatic diseases have been associated with 
accelerated atherosclerosis or other different types of vasculopathy depending 
on the underlying disease, leading to increased cardio- and cerebrovascular 
disease risk. In autoimmune rheumatic diseases besides the traditional risk 
factors, such as hypertension, diabetes, dyslipidemy, smoking and sedentary 
lifestyle, the chronic inflammation and endothelial dysfunction also increase the 
cardiovascular disease (CVD) risk and mortality 
Although some data have been shown previously on the cardiovascular 
involvement and risk factors in Idiopathic Inflammatory Myopathies (IIM), yet 
there have been no studies performed concerning vasculopathy in the disease. 
The reported prevalence of cardiac involvement in patients with PM/DM varies 
between 3% to 100%, based on the definition of the disease, time of the 
investigation in the disease course, etc. The only disease-specific CV 
involvement is myocarditis which occurs rarely and could be associated with the 
presence of auto-antibodies, specially the anti-SRP antibody. Other cardiac 
involvements in IIMs are unspecific; including myocardial infarction, 
conduction abnormalities, arrhythmias, mitral valve prolapse, congestive heart 
failure, hyperdynamic left ventricular contraction, dilated and restrictive 
cardiomyopathy, pulmonary hypertension and pericarditis. The basic 
abnormality is inflammation with necrosis and fibrosis of the myocardium, 
similar to the pathological changes seen in the skeletal muscle. Vascular 
alterations in coronary arteries have also been reported such as vasculitis, 
intimal proliferation, media sclerosis and micro-vessel disease of the heart with 
vasospasm angina. Left ventricular failure occurs due to increased chamber 
stiffness caused by fibrosis or disturbances in calcium regulation. Clinical 
assessment including history and signs of cardiac involvement is important at 
the time of diagnosis as well as during follow-up of myositis patients. 
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According to the international literature beside the malignant and 
infectious diseases, the association of CVD with IIM is usually high. Non-
invasive vascular assessments, including flow mediated dilatation (FMD) of 
brachial artery, carotid artery intima-media thickness (IMT), and augmentation 
index and/or pulse wave velocity of the aorta can reflect the cardiovascular risk 
of these patients. Besides there have been no studies performed concerning 
vasculopathy in these diseases. 
 
1.6. Pregnancy in IIM 
 
Very limited information is available regarding pregnancy outcomes in 
women with myositis. As other systemic autoimmune rheumatic diseases 
(SARD), IIM also affect both fetal and maternal outcomes in pregnancy. Every 
pregnancy in a patient with myositis has to be considered as a high-risk situation 
requiring close monitoring. Crucial issues for improving pregnancy outcomes 
include careful planning, ideal timing and treatment considerations. 
Interestingly, the occurrence or exacerbation of IIM during one pregnancy does 
not necessarily predict the relapse of symptoms in a subsequent pregnancy. Both 
fetal and maternal pregnancy outcome is generally favorable whether pregnancy 
occurred during inactive disease. There are three distinct presentations of 
myositis that can be seen in relation to pregnancy:  
1. flare of pre-existing disease during pregnancy,  
2. pregnancy induced myositis (most often in 1st or 3rd trimester),  
3. postpartum disease onset or flare.   
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2. AIMS 
 
2.1. The interaction of HLA-DRB1*03 allele and smoking for the 
development of Anti-Jo1 antibodies in IIM 
 
Before graduation I’ve studied the genetic backgroud of IIM in our patients and 
the changes in quality of life due to these diseases. As follows I’ve joined to an 
international project researching how genetic and environmental factors, later 
specially smoking and the presence of HLA-DRB1*03 allele affect on anti-Jo1 
positivity in IIM. 
 
2.2. Vascular changes in IIM 
 
The aim of the present study was to assess the flow mediated dilatation of the 
brachial artery by a TensioClinic arteriograph and to measure the thickness of 
carotid artery intima-media, the augmentation index and pulse wave velocity 
using high-resolution ultrasonography in a cohort of IIM patients. We also 
investigated the correlation of these parameters with the traditional risk factors 
of atherosclerosis and overall cardiovascular status within IIM patients. 
Besides we searched any relationship between clinical caracteristics, serological 
findings, therapic management and vascular changes. 
We also examined the role and usefullness of non-invasive angiological 
measurements performing vascular disease in IIM. 
 
2.3. Pregnancy in IIM 
 
As coordinator of an international collaboration I had the opportunity to assess 
the outcome of pregnancy and of the myositis manifestations during pregnancy 
in women with IIM. Our aim was to describe the frquency of maternal and fetal 
complications, finding prognostic markers of pregnancy risk and correlation 
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between clinical symptoms, autoantibody profiles, therapic protocolls and 
pregnancy risk in IIM. 
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3. PATIENTS AND METHODS 
 
3.1. The interaction of HLA-DRB1*03 allele and smoking for the 
development of Anti-Jo1 antibodies in IIM 
During this study, leading by Hector Chinoy, Professor at University of 
Manchester 557 adult-onset IIM patients were recruited from four European 
countries, UK, Sweden, Hungary and the Czech Republic. Patients with PM or 
DM had probable or definite myositis, according to the Bohan and Peter criteria 
and had a confirmed MSA/MAA. 
In the case of Hungarian patients, the muscle biopsy required for diagnosis 
was made from the musculus deltoideus or musculus quadriceps femoris at the 
Institute of Surgery, University of Debrecen. Immunohistochemistry was 
performed in the histology laboratory of Department of Neuropathology. EMG 
tests were performed at the EMG laboratory of the Neurology Clinic. The 
muscle enzyme levels of patients’ serum were detected at the Institute of 
Laboratory Medicine. Muscle weakness was evaluated by manual muscle 
strength test (MMT80). For detection of extramuscular manifestations, like 
myocardial involvement ECG and echocardiography, in some cases myocardial 
MRI were used. In order to objectify the lung involvement, HRCT and diffusion 
capacity measurements were performed. In the assessment of gastrointestinal 
symptoms anamnesis and oesophagus x-ray examination was carried out. Joint 
involvement was measured by physical examination and also X-ray examination 
was performed to exclude erosive arthritis. 
Antibody profiles were analyzed in the Regional Immunological 
Laboratory of University of Debrecen using membrane-based immunoblot or 
ELISA technique Confirmatory and supplementary studies were performed in 
London (Kennedy Insitute) with recombinant protein blot technique, "line-
immuno assay". 
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Smoking history was ascertained through a retrospective questionnaire 
including the statement, “Have you ever smoked as much as one cigarette a day 
for as long as a year?”. 
The genotype was investigated in all the 4 patient groups in local 
laboratories. Subsequently, the DRB1 locus was repeatedly tested in 
Manchester. In the case of Hungarian patients, DNA from the entire peripheral 
blood was isolated. MHC-II alleles, HLA-DBR1, DQA1, DQB1 haplotypes 
were identified by Polymerase Chain Reaction (PCR) and SDS-Polyacrylamide 
Gel Electrophoresis. During PCR, DNA was amplified by using different 
"Master Mixes" for 5 microliters of purified DNA sample. 
During statistical analysis, a chi square test and a Fischer’s exact test were 
used, and logistic regression analysis was performed using Stata software 
(version 9.2, Stata Corp., College Station, TX). 
  
3.2.Vascular changes in IIM 
 
 Twenty-seven patients (21 females, 6 males; mean age at diagnosis: 
39.48 years) with Idiopathic Inflammatory Myopathies (IIMs) were enrolled in 
this study, that were followed-up regularly at the Division of Clinical 
Immunology, Institute of Internal Medicine, University of Debrecen. The 
average age of patients was 39.48 years at diagnosis, 14 of them suffered in DM, 
13 patients had PM. We investigated the development of cardiovascular changes 
(hypertension, peripheral vascular, ischemic heart and cerebrovascular diseases) 
during the disease course, as well as traditional CVD risk factors, such as 
dyslipidemy. 
 For comparison, 38 healthy individuals matched for sex (25 females, 
13 males) and age (mean: 50.3 years) served as controls. None of the controls 
smoked, had overt atherosclerosis, cardiovascular, cerebrovascular, or 
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peripheral vascular disease, hypertension, dyslipidemy, or other confounding 
conditions.  
 During the examination of vascular parameters, the measurements were 
made in the morning, at room temperature of 21 ° C, on an empty stomach. 
Before testing, patients and control persons were rested for 30 minutes in a lying 
position, and strong light or sound effects were eliminated. We asked them not 
to drink coffee or tea or take antioxidants for 24 hours prior to the measurements 
and patients should not take any medicines that could affect the vascular system. 
 The following measurements were made: 
• Assessment of flow-mediated vasodilatation of brachial artery 
• Evaluation of carotid artery intima–media layers’ thickness 
• Assessment of augmentation index and pulse wave velocity in 
the aorta 
Statistical analysis was performed by the SPSS 17.0 software using Pearson's 
correlation analysis for normal distribution variables and Spearman's test for 
non-normal variables. Statistically significant was the p≤0.05 value.  
 
 
3.3. Pregnancy in IIM 
 
I studied clinical symptoms and laboratory parameters before and during 
pregnancy in our IIM patients. 9 women had a pregnancy after myositis 
diagnosis or at the same time. In addition to their data, I collected data of 8 
Czech, 5 Swedish and 1 Polish IIM patients. I examined the course of these 23 
women’s 33 pregnancies. In addition to the retrospective analysis of the clinical 
databases, our patients also completed a questionnaire edited together by the 
participating physicians. The diagnosis was also based on the criteria of Bohan 
and Peter. 
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To characterize the disease activity, manual muscle testing (MMT), serum 
CK, LDH values and presence of skin symptoms were used accordig to IMACS’ 
recommendation. 
Normal delivery was defined when healthy, more than 2500 g weight 
newborn delivered after the ended 37 weeks of pregnancy. Premature delivery 
was defined when the pregnancy ended between its 28 and 37 weeks.  Abortion 
was defined when the pregnancy ended before its 12. weeks, not specified as 
spontaneous or induced. 
Serological profiles were measured in local labs by ELISA or immunoblot 
techniques. Anti-TIF1γ, anti-NXP2, anti-SAE, anti-MDA5 and anti-Zo 
antibody test were performed at University of Bath by immunoprecipitation. 
We used the Fisher’s exact test for statistical analysis and logistic 
regression with the sotware SPSS 17,0. Statistically significant was the p≤0.05 
value.  
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4. RESULTS 
 
4.1. The interaction of HLA-DRB1*03 allele and smoking for the 
development of Anti-Jo1 antibodies in IIM  
We enrolled 557 Caucasian patients with adult IIM in this study: 181 
patients from Hungary, 183 from the Czech Republic, 94 from Sweden and 99 
from the United Kingdom. 75% of patients were female, with a mean age of 48 
years (37-58 years) at time of diagnosis. There was no significant difference 
between nationalities, either considering the sex ratio or the age (p = 0.065). 
50% of patients had PM, 38% had DM and 12% suffered from overlap myositis. 
In the Hungarian population there were significantly fewer DM cases compared 
to the others (OR: 0.36, 95% confidence interval (CI) (0.24-0.54), p <0.0001). 
Overlap cases, however, were significantly more frequent (OR 3.06, CI: 1.83-
5.14, p <0.0001). 
There was no significant difference in the frequency of HLA-DRB1*03 
allele in the study in the 4 patient groups. The DRB1*03 allele was detected in 
32% of Hungarian patients, 43.2% in Czech Rep., 54.3% in Sweden and 52.5% 
in the UK. 
Anti-Jo1 autoantibody positivity was confirmed in 21% of patients, 
specially in 16% of Hungarian patients. There was no significant difference in 
the antibody frequency in the 4 subgroup. 
39% of our patients were smokers, most of them from the UK, least of 
them in Hungary. A significant difference had been shown in the distribution of 
smokers (p <0.0001) in the 4 nationalities. 
Examinig the 4 nations together, the proportion of smokers was 
significantly high among anti-Jo1 positive patients. 50% of antibody positive 
patients were smokers, while in the anti-Jo1 negative group only 36% used 
cigarettes (OR: 1.83, 95% CI: 1.18-2.83, p = 0.004). In the 4 patient populations, 
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only the Hungarian patients showed significant differences between the smoking 
habits of anti-Jo1 positive and negative patients. 45% of our antibody positive 
patients were smoked, whereas in the antibody negative group, only 17% (OR: 
3.94, 95% CI: 1.53-9.89, p = 0.0009). 
 Investigating the genetic background, a close correlation was verified 
between carrying HLA-DRB1*03 allele and anti-Jo1 antibody positivity. The 
presence of the HLA-DRB1 * 03 allele was detected in 74% of antibody positive 
IIM patients (OR 5.55, CI: 3.42-9.14, p <0.00001). 
The frequency of HLA-DRB1*03 allele was higher for smoking patients 
than for non-smoker patients. The difference was also statistically significant 
only for Hungarian patients, 59% vs. 25% (OR: 4.39, CI: 1.96-9.92, p 
<0.00001). 
Subsequently, we investigated the relationship between smoking and the 
presence of HLA-DRB1*03 allele in conjunction with anti-Jo1 autoantibody 
positivity. In order to ensure that the low sample size of each group does not 
affect the statistical significance of the results, in this case, the patients were 
divided into groups independently from nationality. Since all 4 nationalities 
belong to the Caucasus race, genetic features do not affect the results obtained 
if individuals of different nationalities are classified into one group, and examine 
exclusively the smoking habits and anti-Jo1 positivity. The HLA-DRB1*03 
negative, non-smoking patients were considered as control group, and their 
results were compared to the others. 
Comparing to the controls, in the HLA-DRB1*03 carrier group, whether 
smokers or not, anti-Jo1 positivity was more common. In non-smokers among 
HLA-DRB1*03 positive patients, 39 cases showed antibody positivity, a 2.1-
fold increase to the control group (where n = 18, p <0.0001). For HLA-
DRB1*03 positive smokers this number is 47 (2.6 times more common than in 
the control group p <0.0001). Similarly, more frequent antibody positivity was 
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found in smokers carrying DRB1*03 alleles compared to non-smokers carrying 
the DRB1*03 allele, although the result was not significant (p = 0.08). 
A similar tendency was also observed comparing male and female patients. 
In both male (4 vs. 15) and female patients (14 vs. 32), more smoker and DRB1 
* 03 allele carrier showed anti-Jo1 autoantibody positivity. In men, the 
frequency of anti-Jo1 antibodies comparing to the control group (non-smoking, 
DRB1*03 negative male) was 3.75 times higher in the smoking, DRB1*03 
positive group (p = 0.005). In women, the carriage of the DRB1*03 allele 
increases the chance of the appearance of anti-Jo1 antibody alone (n = 33 and 
32 vs n = 14). There was no significant difference in the frequency of anti-Jo1 
antibodies among smokers and non-smokers in DRB1*03 negative patients. For 
men this number is 4 vs. 6, females 14 vs 5. 
 
4.2. Vascular changes in IIM 
 
The clinical investigation of CVDs in IIMs showed that 66,7% of patients 
(n=18; 13 women and 5 men) had hypertension and 29,6% of our patients (n=8; 
6 women and 2 men) had ischemic heart disease (IHD) and/or peripheral 
vascular disease (PAD).  None of the patients had major cardio-or 
cerebrovascular hit. I also examined other cardiovascular diseases, such as 
valvulopathy, myocarditis, pericarditis or Raynaud’s syndrome. 
 
Flow-mediated vasodilatation of brachial artery (abFMD) 
Concerning abFMD we observed decreased abFMD in myositis patients, 
although the result was not significant (p=0,065), while in DM a significantly 
decreased abFMD was found compared to healthy subjects. Subsequently we 
assessed correlations between the traditional risk factors of atherosclerosis and 
cardiovascular diseases. We found significantly negative correlation between 
the triglyceride levels and flow mediated dilatation (R:-0,412, p:0,041). 
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Neither hypertension, IHB + PAD, Raynaud phenomenon, myocarditis, 
pericarditis, nor valvulopathies were correlated with the abFMD values. I did 
not find any relation between blood pressure values before the tests, cholesterol, 
LDL-C, HDL-C levels, smoking and abFMD in our patients 
The lipid parameters of the control group and their blood pressure values 
prior the study had no correlation with the abFMD values. 
 
Carotid artery intima–media thickness (acIMT) 
Intima-media thickness of the carotid artery showed also a tendency of 
increased arterial thickness in myositis patients compared to healthy controls 
(0,61 mm vs. 0,59 mm; p:0,28), which was more pronounced in DM patients 
(0,64 mm vs. 0,59 mm; p:0,07), although the difference did not reach statistical 
significance. We also found a significant positive correlation between the values 
of systolic blood pressure and the thickness of the carotid artery intima-media 
in IIMs. We found significantly increased carotid IMT thickness in patients with 
systolic hypertension compared to healthy controls. Significant differences in 
acIMT have been found both in patients with IHD+PAD compared to healthy 
controls. The mean carotid IMT of IHD+PAD patients was 0,69 mm, in healthy 
controls this value was 0,59 mm (p:0,04). 
No correlation was found between diastolic hypertension, triglyceride, 
cholesterol, LDL-C, HDL-C values, smoking and acIMT in our patients.  
The lipid parameters of the control group and their blood pressure values 
prior to the study had no correlation with acIMT. 
The acIMT values of myositis patients with previously documented 
hypertension were significantly higher compared to healthy subjects. 
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Augmentation index (AIx) and pulse wave velocity (PWV) in the aorta 
Concerning pulse wave velocity, we also found a tendency of increased 
arterial stiffness in the aorta both in all IIM patients (8,79 m/s vs 8,43 m/s; 
p:0,68) and in DM (8,78 m/s vs. 8,43 m/s; p:0,78), compared to healthy 
individuals. Concerning the traditional risk factors significantly positive 
correlation have been found between the triglyceride levels and the 
augmentation index (AIx) in myositis patients (R:0,567, p:0,029). We verified 
a clear significant difference in pulse wave velocity between IHD+PAD patients 
and healthy individuals (p<0.001). Neither hypertension, Raynaud 
phenomenon, myocarditis, pericarditis, nor valvulopathies have been associated 
with the pulse wave velocity. 
 
Moreover we investigated associations between auto-antibody positivity 
and vascular abnormalities. 8 patients showed MSA positivity (5 PM, 3 DM), 
among them in 6 cases anti-Jo1 autoantibodies were detected. One of our 
patients was positive for anti-Jo1 with severe interstitial lung disease. On the 
grounds of pulmonary fibrosis, serious pulmonary arterial hypertension 
developed followed by fatal right and left ventricular failure. One of them had 
pulmonary fibrosis with slight right ventricular failure. Other cardiovascular 
diseases like IHD, PAD and hypertension did not present in the Jo1 positive 
group. Five patients were positive to antiphospholipid antibodies, while 2 had 
anti-Mi2 autoantibodies; no specific vascular changes were found in these 
groups. 
Concerning the therapy, we have not found any significant differences 
between groups. Overall, the cardiovascular changes were more frequent in 
patients who needed combined immunosuppressive treatment. 
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4.3. Pregnancy in IIM 
 
This project consists of retrospective data analysis from 9 Hungarian, 8 
Czech, 5 Swedish and 1 Polish, a total of 23 female IIM patients and 33 
pregnancies. The mean age of patients was 23.3 years (7-37 years) at diagnosis. 
Diagnosis of PM were established in 10 cases, DM was observed in 10, JDM in 
3 patients. We observed overlap syndrome in three cases: 2 cases of PM with 
SLE and SSc, and 1 case of DM with RA. Cancer-associated myositis did not 
occur in either case. 
Regarding clinical symptoms, the most frequent complaint at diagnosis 
was muscle weakness in 95.6% (n=22) of patients. In addition, extramuscular 
manifestations were also observed. Most commonly, arthritis (52.17%, n=12), 
interstitial alveolitis (43.48%, n=10), and mechanic's hand (43.48%; n=10) 
occurred. 
Myositis specific autoantibodies were detected in 8 women's serum at 
diagnosis, in 6 cases anti-Jo1 and in 2 anti-Mi2 antibodies. Considering 
myositis.associated antibodies, anti-Pm/Scl (n=2) and anti-SSB (n=1) 
antibodies were shown. Other autoantibodies, like anti-histone (n=1), double-
stranded DNA (dsDNA, n=2), and anti-phospholipid antibodies, namely anti-
cardiolipin antibody (n=5) were also present. 
Thirty-three of our patients had a total of 33 pregnancies, the mean age was 
29.04 years at the beginning of their pregnancy. An average of 68.8 months (0-
228) passed between myositis diagnosis and first pregnancy. Pregnancy-induced 
myositis was observed in 3 cases in the 8th, 17th and 28th weeks of pregnancy 
in 1-1 SS-PM, RA-DM and DM patients. 
In 42.4% of the pregnancies (n=14) fetal complications have been 
observed. These pregnancies were terminated between gestational week 7 and 
31. In 3 cases intra-uterine deaths, in 6 cases miscarriages occurred, 4 of which 
were spontaneous and 2 induced abortions. In the latest two cases abortion were 
 19 
 
induced due to an immunological indication, like the mother's serious, active 
illness and intake of contraindicated immunosuppressive agents causing fetal 
malformation. In addition, extra-uterine gravidity in one case, and also 4 
premature births were confirmed. Infants born from complicated pregnancies 
had an average birth weight of 2350 g (168-3220g) and were born on 35.5 weeks 
(35-36). According to our information, these children later grown up healthy. 
The above-mentioned 14 fetal complications were observed in 9 patients, 
including 6 PM and 3 DM or JDM. Due to the active illness, 7 mothhers (PM=5, 
DM=2) required immunosuppressive therapy besides corticosteroid treatment 
before, during or after pregnancy. In 3 cases anti-Jo1 autoantibody positivity 
was detected in serum of these patients, and anti-cardiolipin and anti-Pm / Scl 
autoantibodies were also detected in 1-1 cases. In 10 cases of complicated 
gravidity, conception occurred in the active period of maternal disease, 2 times 
in remission. 2 pregnancy-induced myositis were observed, one of which ended 
with spontaneous abortion and the other with premature labor. Myositis 
remained active after delivery in all these cases.  
Based on our results, fetal complications were more common in 
polymyositis than in dermatomyositis (p = 0.0729). The relative risk of fetal 
complication in PM was 1,923 (95% confidence interval; 1,041-3,553). 
Probably, besides the PM subgroup, maternal disease activity before or during 
pregnancy and the presence of autoantibodies may be a risk factor for the 
development of fetal complications. In the logistic regression analysis, the 
association of arthritis (OR: 7.5, p: 0.032, 95% CI (1.19-47.77)) and anti-Jo1 
autoantibody positivity (OR: 8.9, p: 0.023; 95% CI (1.34-58.88) showed 
correlation with complications. 
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5. DISCUSSION 
 
5.1. The interaction of HLA-DRB1*03 allele and smoking for the 
development of Anti-Jo1 antibodies in IIM 
 
During the observation of four independent European adult IIM patient 
groups, we tried to find out whether the same smoking-genotype-autoantibody 
relationship as previously described in RA can be detected in IIM. 
In our work, the effect of the HLA-DRB*03 allele positivity and smoking 
were studied on the expression of the most common myositis-specific 
autoantibody. 
In our patients, the prevalence of anti-Jo-1 autoantibodies was around 20%, 
which corresponds to previously published data. Interestingly, in all 4 cohorts, 
there were more smokers among anti-Jo1 positive IIM patients, but this 
difference only reach statistical significance in Hungarian patients. Carrying the 
HLA-DRB1*03 allele was also significantly more frequent in Hungarian, 
smoker IIM patients. Overall, the incidence of anti-Jo-1 antibody is the highest 
in the HLA-DRB1*03 positive, smoker patient group. 
Our findings suggest that smoking is likely to increase the risk of 
developing IIM in individuals carrying HLA-DRB1*03 alleles. Our current 
study has shown that the risk of anti-Jo1 autoantibody expression is higher in 
IIM patients who either smoke and/or carry the HLA-DRB1*03 allele, but due 
to the absence of age-matched healthy control populations we can not state that 
these conditions increase the risk of IIM. Our results also indicate that 
individuals with HLA-DRB1*03 alleles who had ever smoked has a tendency 
to anti-Jo1 autoantibody production although statistically significant correlation 
between these 3 parameters could not be verified. It is also possible that HLA-
DRB1*03 does not independently influence the appearance of anti-Jo1 
antibodies. 
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Overall, we assume that the presence of HLA-DRB1*03 alleles and 
smoking together may present a risk for the development of IIM. It is also likely 
that the risk of the appearance of anti-Jo-1 antibodies continues to increase in 
those IIM patients who are smokers and have one or more HLA-DRB1*03 
copies. These findings help understanding the etiology of IIM and confirm the 
interaction of the previously described environmental and genetic risk factors in 
disease onset. 
 
5.2. Vascular changes in IIM 
 
Our present findings underlined that similarly to other systemic 
autoimmune diseases, impaired abFMD, PWV and increased acIMT were 
present in IIMs, suggesting the vasculopathy in pathomechanism and increasing 
the risk of simoultaneous cardiovascular disease. We can establish that the 
assessments of flow mediated dilation of the brachial artery and the arterial 
stiffness of the aorta and carotid artery intima-media thickness can be beneficial 
to predict the CVD risk in myositis patients.  
Our findings also confirmed that in DM more vascular abnormalities could 
be found than in PM. These results could arise from the differences in the 
pathomechanism of PM and DM. Although striated muscle is the main target of 
the autoimmune mechanism in both disease entities, in DM, the intramuscular 
small blood vessels are more dominant effectors’ sites, while in PM, the muscle 
fibres are more direct targets. And more recently, changes in the vascular 
components were proven to be the primary lesion in this disease because 
microtubular inclusions and micro vacuoles in endomysial capillaries and MAC 
deposits were recognized even in otherwise normal muscle of patients with DM. 
Among traditional risk factors, hypertriglyceridemy, hypertension leading 
to the development of ischemic heart or peripheral vascular diseases could be 
also implicated as one of the forms of vasculopathy in IIM. The elevated 
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triglyceride levels in our patients could be explained also with sedentary life 
style due to muscle weakness and impaired physical activity beside the 
nutritional and hereditary susceptibility of hypertriglyceridemy. We have not 
found any major cardiovascular events, such as acute myocardial infarction, 
stroke or critical limb ischemia in our patients. 
.  
We haven’t found any correlation between vascular changes and myositis 
treatment, but we cannot exclude that the immunosuppressant treatment could 
also decrease the endothelial dysfunction in chronic inflammatory diseases.  
Our group is the first who measured objectively the endothelial 
dysfunction on such a large myositis population. These results not showed that 
myositis alone would affect the patient's vascular status. I suggest that in 
addition to the underlying disease, associated cardiovascular diseases and 
traditional risk factors play a part in the development of vacular disorders in our 
patients. This fact emphasise the importance of primary and secondary 
prevention in decreasing the CVD risk, for example smoking cessation, 
achievement of appropriate lipid levels, tension control, regular cardiovascular 
status assessment. 
 
5.3. Pregnancy in IIM 
 
IIMs are rare autoimmune disease characterized by female dominance, but 
disease onset occurs during childbearing years only in 12-14 % of cases. Limited 
information is found in the literature, I found data on a total of 89 patients and 
121 pregnancies, of whom 25.8% (n = 23) participated in my project. The 
maternal disease were DM in 48 and PM in 33 cases. There has been no accurate 
data about myositis subgroup in 8 women’s pregnancy. Both fetal and maternal 
pregnancy complications are often reported also in PM and DM and there are 
data about in pregnancy-induced maternal illness. In contrast, inactive or well-
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controlled maternal disease at the time of conception imply less risk both fetal 
and maternal complications. In 34 cases, limited or incomplete data is available 
about maternal illness or fetal outcomes. In the other, preciously published cases 
97 cases, the mother suffered from PM in 40 and of DM in 57 cases. In DM 
patients, the myositis of the mother was inactive during 23 pregnancies, active 
in 8 gravidity and pregnancy induced DM was reported in 16 cases. Examination 
of PM mothers showed inactive disease during 12, active in 13 and pregnancy- 
induced mositis in 15 pregnancy. The number of reported fetal complications 
during pregnancies were 21 in DM mothers, respectively 22 in PM. Silva et al. 
reported the first retrospective study about this topic, about the examination of 
33 ladies 44 pregnancies between 1966 and 2000. They assumed that the best 
pregnancy outcomes for both mother and foetus would be expected in case of 
inactive maternal illness. In pregnancies concieved during active maternal 
illness, they observed 33% of fetal deaths and 43% intrauterine growth 
retardation.  
Overall based on previosly published data, there is no significant difference 
in fetal outcomes weather the mothers have PM or DM. Considering fetal 
complications, only active or pregnancy-induced maternal myositis represents a 
risk factor. Myositis-specific fetal complications have not been identified so far. 
The most common complications were abortion and intrauterine fetal 
retardation. Newborns did not show the symptoms of IIM, the authors had not 
reported any skin symptoms or muscle weakness. 
My results confirm the observation as active maternal myositis increases 
the the frequency of fetal complications. No myositis specific fetal 
complications were found. Neither the nature nor the timing of the complication 
differ from others observed in systemic immune diseases. The most common 
fetal complications were abortion and premature birth. Overall, the birth weight 
of newborns is lower in active and pregnancy-induced maternal myositis. In 
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addition, pregnancies of patients with active or pregnancy-induced myositis 
terminated earlier than those of asymptomatic patients. There was no significant 
difference in the type of fetal complications between PM and DM mothers. The 
degree of disease activity (from mild to severe) did not significantly affect the 
fetal outcomes. None of the infants showed any symptoms of myositis, that’s 
why muscle enzyme levels were not checked. 
In our project fetal complications in patients with polymyositis were more 
common than in dermatomyositis (p=0.0729). The relative risk of fetal 
complication in PM is 1.923. Because of the retrospective analysis, neither 
histopathological nor detailed immunological laboratory results were available 
for all patients, I can only assume the cause of more frequent fetal complications 
observed in PM. The effect of chronic inflammation and the immune response 
induced by fetal antigens could lead to complications, and also the influence of 
myositis specific and associated autoantibodies cannot be excluded. Based on 
the literature, the involvement of the uterus can not be assumed. Nevertheless, 
it can not be ruled out that myometrium involvement or problems with 
implantations due to chronic inflammation are in the background of abortions 
and premature births.  
In 26 of the observed 33 pregnancies, mothers were received corticosteroid 
monotherapy or were medication-free prior to pregnancy, thus the teratogenic 
side effects of immunosuppressive agents may be excluded as risk factor for the 
fetus. 
In the logistic regression analysis, joint involvement and anti-Jo1 
autoantibody positivity were associated with the development of fetal 
complications. The anti-Jo1 autoantibody is known to be most commonly 
associated with anti-synthetase syndrome in wich disease one of the leading 
symptom is symmetric, non-erosive arthritis. In addition, arthritis and arthralgia 
are common in all IIM subgroups, so these results are not surprising. 
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The outcome of pregnancies is generally good for mothers. Neither general 
nor obstetrical complications have been observed. The onset or exacerbation of 
the underlying disease can cause maternal complaints. Most of the exacerbation 
of IIM can be controlled by increasing the steroid dosage until delivery. In some 
cases the symptoms of IIM disappeared after delivery, no further treatment was 
needed. In severe, rapid progressive cases IVIG treatment could be the best 
choice. During pregnancy, the proportion of T helper cells is shifting to the Th2 
group, and the exposure of fetal antigens is constantly changing the activity of 
the maternal immune system. All this can explain the exacerbation of IIM during 
pregnancy and also pregnancy-induced cases. 
No maternal complication was observed in our study, most delivery 
occured without any problem, no information is available about 
rhabdomyolysis, myoglobinuria or contractional weakness. Except for 2 cases, 
the mother's underlying disease was well-controlled by corticosteroid 
monotherapy during pregnancy. In 33.3% (n=11) of cases, immunosuppressive 
treatment was performed post partum. 
My results also show that pregnancies in IIM patients has to be considered 
as high risk for both the fetus and the mother and require increased observation 
and multidisciplinary collaboration (internal medicine, gynecologist and 
neonatologist). Especially in pregnancies with active maternal illness because 
of the increased incidence of complications and premature births. Planning and 
ideal timing of pregnancy and continous consultation with the physician is 
optimal for both mother and fetus. 
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6. SUMMARY OF NEW RESULTS 
 
1. Carrying the HLA-DRB1*03 allele in Hungarian IIM patients significantly 
increases the risk of developing anti-Jo1 antibody, and this risk is further 
enhanced by smoking in men. 
 
2. In myositis increased vascular stiffness could be observed, indicating 
endothelial dysfunction and may increase cardiovascular risk. 
 
3. Vascular changes are more pronounced in DM than in PM. 
 
4. Besides the underlying myositis, associated cardiovascular diseases and 
traditional risk factors also play a role in the development of vacular 
changes in myositis patients. 
 
5. Fetal complications are more common in polymyositis than in 
dermatomyositis (p = 0.0729). The relative risk of fetal complication in 
PM is 1.923. 
 
6. Considering the characteristics of maternal disease, joint involvement and 
anti-Jo1 autoantibody positivity negatively affect the fetal outcome of 
pregnancy. 
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8. APPENDIX 
  
 
Genetic reasearches were funded by Myositis Support Group (UK), a 
Swedish Research Council, the Swedish Rheumatism Association, Ministry of 
Education, Youth and Sports in the Czech Republic, King Gustaf V 80 Year 
Foundation, and by Hungarian ETT grant (No: ETT 2 FAE 1 KCOO90819). 
 
"Vascular research was organised within the following program: TÁMOP 
4.2.4.A/2-11-1-2012-0001 National Excellence Program - Local convergence 
program providing  personnel support in development and operation for students 
and researchers. The project was funded by the EU and the European Social 
Fund." 
 
Pregnncy study was organized within the ESF EuMyoNet Research 
Networking Programme.  
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